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The ability of the immune system to function as 
an  extrinsic  tumor  suppressor  and  effectively 
eliminate,  control,  and/or  sculpt  developing   
tumors forms the basis of the cancer immunoedit­
ing hypothesis (Shankaran et al., 2001; Dunn   
et al., 2002, 2004). There is strong experimental 
support for all three phases of cancer immuno­
editing, elimination, equilibrium, and escape, and 
many of the key cellular mediators and immune 
effector  molecules  involved  in  host  protection 
from tumor development have been identified 
(Dunn et al., 2006; Smyth et al., 2006; Koebel   
et al., 2007; Schreiber et al., 2011; Vesely et al., 
2011). The IFNs, both type I (IFN­/) and 
type II (IFN­), have emerged as critical compo­
nents of the cancer immunoediting process, and 
work is ongoing to define their respective roles in 
promoting antitumor immune responses.
Early studies supporting the existence of 
cancer immunoediting revealed an important 
function for IFN­ in suppressing tumor de­
velopment in models of both tumor transplan­
tation and primary tumor induction (Dighe   
et al., 1994; Kaplan et al., 1998; Shankaran   
et al., 2001; Street et al., 2001, 2002). Specifi­
cally, IFN­ was found to induce effects on 
both tumor cells (Dighe et al., 1994; Kaplan   
et al., 1998; Shankaran et al., 2001; Dunn et al., 
2005) and host cells (Mumberg et al., 1999; 
Qin and Blankenstein, 2000; Qin et al., 2003). 
Subsequently, an essential function for endog­
enous type I IFN in cancer immunoediting was 
established (Dunn et al., 2005; Swann et al., 
2007). Gene­targeted mice lacking the type I   
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Cancer immunoediting is the process whereby the immune system suppresses neoplastic 
growth and shapes tumor immunogenicity. We previously reported that type I interferon 
(IFN-/) plays a central role in this process and that hematopoietic cells represent critical 
targets of type I IFN’s actions. However, the specific cells affected by IFN-/ and the 
functional processes that type I IFN induces remain undefined. Herein, we show that type I 
IFN is required to initiate the antitumor response and that its actions are temporally  
distinct from IFN- during cancer immunoediting. Using mixed bone marrow chimeric mice, 
we demonstrate that type I IFN sensitivity selectively within the innate immune compart-
ment is essential for tumor-specific T cell priming and tumor elimination. We further show 
that mice lacking IFNAR1 (IFN-/ receptor 1) in dendritic cells (DCs; Itgax-Cre+Ifnar1f/f 
mice) cannot reject highly immunogenic tumor cells and that CD8+ DCs from these mice 
display defects in antigen cross-presentation to CD8+ T cells. In contrast, mice depleted of 
NK cells or mice that lack IFNAR1 in granulocytes and macrophage populations reject these 
tumors normally. Thus, DCs and specifically CD8+ DCs are functionally relevant targets of 
endogenous type I IFN during lymphocyte-mediated tumor rejection.
©  2011  Diamond  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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factor (CD8+ DCs and CD103+ DCs, hereafter referred to as 
CD8+ lineage DCs) was shown to play an important role in 
cross­presenting viral and tumor antigens, and mice lacking   
these cells fail to reject highly immunogenic unedited sarcomas   
(Hildner et al., 2008; Edelson et al., 2010). However, it remains 
unknown whether the cross­presenting activity of these cells re­
quires type I IFN to induce tumor immunity.
In the current study, we have investigated the host cell tar­
gets of endogenous type I IFN during the rejection of highly 
immunogenic, unedited tumors. We demonstrate that IFN­/ 
acts early during the initiation of the immune response and 
IFN receptor developed more carcinogen­induced primary 
tumors than WT control mice (Dunn et al., 2005; Swann   
et al., 2007), and antibody­mediated blockade of the IFN­/ 
receptor in WT hosts abrogated rejection of immunogenic 
transplanted tumors (Dunn et al., 2005). The activity of   
endogenous type I IFN was mediated not by its direct effects 
on the tumor but by its actions on host cells, specifically on   
hematopoietic­derived host cells (Dunn et al., 2005). Collec­
tively,  these  findings  highlight  a  difference  between  the 
antitumor activities of the IFNs, wherein tumor cell respon­
siveness to IFN­ but not IFN­/ and host cell responsive­
ness to both IFN­ and IFN­/ are crucial for tumor 
rejection. However, the relevant host cell targets and anti­
tumor functions of IFN­/ and IFN­ remain undefined 
because of the nearly ubiquitous expression of IFN­/ and 
IFN­ receptors and the pleiotropic effects they induce.
Although initially defined by their antiviral activity, the type 
I IFNs are potent immunomodulators that shape host immunity 
through direct actions on innate and adaptive lymphocytes. The 
enhancement of NK cell cytotoxicity by IFN­/ in the setting 
of viral infection was one of the earliest such effects to be recog­
nized (Biron et al., 1999). Type I IFN directly augments NK 
cell–mediated killing of virally infected or transformed cells and 
indirectly  promotes  the  expansion  and  survival  of  NK  cells 
through IL­15 induction (Nguyen et al., 2002). Furthermore, in 
models of NK cell–dependent tumor rejection, host cell respon­
siveness to IFN­/ was shown to be important for control of 
tumor growth and metastasis (Swann et al., 2007). Type I IFN 
can also act directly on T and B lymphocytes to modulate their 
activity and/or survival. Treatment with IFN­/ in vitro pro­
longed the survival of activated T cells (Marrack et al., 1999) and 
augmented clonal expansion and effector differentiation of 
CD8+ T cells (Curtsinger et al., 2005) through cell­intrinsic 
IFN­/ receptor signaling. Similarly, type I IFN responsive­
ness in T cells was required in vivo for optimal clonal expansion 
of antigen­specific CD8+ and CD4+ T cells during viral infec­
tion (Kolumam et al., 2005; Havenar­Daughton et al., 2006; 
Thompson et al., 2006) as well as for CD8+ T cell priming after 
immunization with antigen and IFN­ (Le Bon et al., 2006a).   
B cell differentiation, antibody production, and isotype class 
switching were also enhanced by type I IFN’s effects either di­
rectly on B cells or indirectly via effects on T cells (Coro et al., 
2006; Le Bon et al., 2006b) and DCs (Le Bon et al., 2001).
Type I IFN also directly enhances the function of DCs, 
which are central to the initiation of adaptive immune responses 
(Steinman and Banchereau, 2007). IFN­/ induces DC matu­
ration, up­regulates their co­stimulatory activity and enhances 
their capacity to present or cross­present antigen (Luft et al., 
1998; Gallucci et al., 1999; Montoya et al., 2002). For example, 
coinjection  of  IFN­/  plus  antigen  (Gallucci  et  al.,  1999;   
Le Bon et al., 2001, 2003) or injection of DC­targeted antigen in 
combination with the IFN­/ inducer polyinosinic:polycyti­
dylic acid (polyI:C; Longhi et al., 2009) stimulated CD8+ T cell 
priming, humoral responses, and development of CD4+ Th1 
responses in vivo. Recently, a subpopulation of DCs whose de­
velopment depends on expression of the BATF3 transcription 
Figure 1.  Early requirement for IFN-/ during rejection of highly 
immunogenic tumor cells. (A) Untreated WT and Rag2/ mice or WT 
mice injected i.p. with either IFNAR1-specific MAR1-5A3 mAb or isotype 
control GIR-208 mAb 1 d prior were s.c. injected with 106 H31m1 tumor 
cells, and tumor size was measured over time. Data represent mean tumor 
diameter ± SEM of 12–16 mice per group from at least three independent 
experiments. (B–D) WT mice were injected with 106 H31m1 cells (at day 0) 
and treated beginning on the indicated day with MAR1-5A3 (B), IFN-–
specific H22 mAb (C), or a mixture of anti-CD4/anti-CD8/anti–IFN- mAbs 
GK1.5/YTS-169.4/H22 (D), and tumor growth was monitored. For each time 
point, groups of mice were treated in parallel with the respective isotype-
matched control mAb, and the data are presented as percent tumor growth 
over the control group. Results are from two to four experiments with 14–20 
(ctrl/MAR1-5A3), 10–20 (ctrl/H22), or 6–11 (ctrl/cocktail) WT mice per 
group. The kinetics of tumor growth in individual mice is shown in Fig. S1.JEM Vol. 208, No. 10 
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cells were rejected when transplanted into naive syngeneic WT 
mice  either  left  untreated  or  pretreated  with  GIR­208,  the   
tumors grew progressively in WT mice pretreated with MAR1­
5A3 (Fig. 1 A). Similarly, MAR1­5A3 treatment on day 4 or 6 
(relative to tumor injection at day 0) blocked rejection in >50% 
of injected mice. In contrast, IFN­/ receptor blockade at later 
time points did not inhibit rejection (Fig. 1 B and Fig. S1). In 
parallel experiments, blockade of IFN­ via treatment with neu­
tralizing IFN­–specific H22 mAb (Schreiber et al., 1985) re­
vealed a more prolonged requirement for the actions of IFN­ 
during H31m1 rejection (Fig. 1 C). Cohorts of mice were also 
treated with a mixture of mAbs that deplete CD4+ and CD8+ 
cells  and  neutralize  IFN­  (GK1.5  [Dialynas  et  al.,  1983], 
YTS169.4 [Cobbold et al., 1984], and H22, respectively) to 
broadly disrupt host immunity. In this group, progressively 
growing tumors were observed in a substantial proportion of 
mice treated as late as day 14 with the anti­CD4/CD8/IFN­ 
mAb cocktail (Fig. 1 D). Collectively, these data demon­
strate that the obligate functions of type I IFN are required 
only for initiating the immune response to tumors.
A tissue-restricted role for type I IFN  
during tumor rejection
To characterize the critical host cells responding to type I IFN 
during initiation of the antitumor response, we transplanted 
H31m1 tumor cells and cells from a second unedited MCA 
sarcoma, d38m2, into bone marrow chimeras with selective 
IFN­/ sensitivity. These tumor cell lines were selected be­
cause we previously showed that their rejection required type I   
IFN responsiveness at the level of the 
host (Dunn et al., 2005). As reported 
previously, both cell lines were rejected 
when transplanted into immunocom­
petent WT  mice  but  formed  pro­
gressively  growing  tumors  in  either 
Rag2/ or Ifnar1/ mice (Fig. 2,   
A  and  B). We  now  show  that  both 
lines grew progressively in Ifnar1/ → 
Ifnar1/ bone marrow chimeras and 
that innate immune cells represent the essential responsive cells 
for the generation of protective antitumor immunity. Whereas 
type I IFN–unresponsive mice showed a defect in the priming 
of tumor­specific CTLs, reconstitution of IFN­/ sensitivity 
in innate immune cells was sufficient to restore this deficit and 
resulted in tumor rejection. Within the innate immune com­
partment, we find no evidence of an essential role for NK cells 
or for type I IFN sensitivity in granulocytes or macrophages, 
but rather find that the actions of IFN­/ on DCs are re­
quired for development of tumor immunity in vivo and play 
an important role in promoting the capacity of CD8+ lineage 
DCs to cross­present antigen to CD8+ T cells. These results 
thus identify DCs and specifically CD8+ lineage DCs as key 
cellular targets of type I IFN in the development of protective 
adaptive immune responses to immunogenic tumors.
RESULTS
Early requirement for type I IFN  
during the antitumor response
We previously showed that blockade of type I IFN signaling by 
pretreatment of mice with the IFNAR1 (IFN­/ receptor 1)­
specific MAR1­5A3 mAb (Sheehan et al., 2006) abrogated   
rejection of highly immunogenic sarcomas derived from   
3­methylcholanthrene (MCA)–treated Rag2/ mice (termed 
unedited tumors; Dunn et al., 2005). To dissect the temporal   
requirements for IFN­/’s actions during the antitumor im­
mune response, we treated WT mice with either MAR1­5A3 
or isotype control GIR­208 mAb at different times after injec­
tion of unedited H31m1 MCA sarcoma cells. Whereas H31m1 
Figure 2.  Nonoverlapping host cell tar-
gets for IFN-/ and IFN- during tumor 
rejection. (A–C) Control mice and the indi-
cated bone marrow chimeras with selective 
IFN-/ sensitivity (A and B) or IFN- sensi-
tivity (C) in hematopoietic versus nonhemato-
poietic cells were injected s.c. with 106 H31m1 
(A) or d38m2 (B and C) unedited MCA sar-
coma cells, and growth was monitored. Data 
are presented as mean tumor diameter ± SEM 
over time or the percentage of tumor-positive 
mice per group from two to three (A and B) or 
five (C) independent experiments with group 
sizes as indicated. Hematopoietic reconstitu-
tion of all Ifnar1/ and Ifngr1/ bone  
marrow chimeras was confirmed by flow cytom-
etry at the conclusion of each experiment.1992 Type I IFN effects during tumor rejection | Diamond et al.
was not caused by incomplete hematopoietic reconstitution, 
we confirmed normal cellularity and immune cell percent­
ages in the spleen, demonstrated normal functional immune 
reconstitution, and ruled out the presence of radio­resistant 
tissue­resident  leukocytes  within  the  tumor  environment 
(Figs. S3–S5). These data not only establish an important role 
for IFN­ sensitivity in both hematopoietic and nonhemato­
poietic cells during tumor rejection but also reveal a differ­
ence between the broad cellular requirements for IFN­ as 
opposed to the tissue­restricted requirement for IFN­/ 
during elimination of the same tumor.
Innate immune cells are the critical targets of type I IFN
To examine the role of type I IFN’s actions on innate versus 
adaptive immune cells, we generated mixed bone marrow 
chimeras with selective type I IFN sensitivity within the   
hematopoietic compartment. Reconstitution of lethally irradi­
ated Ifnar1/ mice with a 4:1 mixture of Rag2/ and Ifnar1/ 
hematopoietic stem cells (HSCs) yielded mice with IFN­/ 
responsiveness solely in innate immune cells (Rag2/ +   
Ifnar1/ → Ifnar1/ chimeras, hereafter referred to as innate   
chimeras). Conversely, reconstitution of Ifnar1/ mice with 
a 4:1 mixture of Rag2/ × Ifnar1/ 
double KO mice (Rag2/Ifnar1/) 
and WT HSCs produced chimeras with 
IFN­/–sensitive T and B lympho­
cytes but a predominantly IFN­/–
insensitive innate immune compartment 
(Rag2/Ifnar1/ + WT → Ifnar1/; 
Ifnar1/  →  Rag2/  chimeras  (IFN­/  sensitivity  only   
in nonhematopoietic cells) but were rejected in WT → WT 
chimeras and WT → Ifnar1/ chimeras (IFN­/ sensitivity 
only in hematopoietic cells). These results thus extend, to two 
additional tumors, our prior finding that type I IFN sensitivity 
within the hematopoietic compartment is both necessary and 
sufficient for tumor rejection (Dunn et al., 2005).
Because the rejection of immunogenic sarcomas also re­
quires IFN­ sensitivity within the host (Fig. S2), we wanted 
to determine whether IFN­/ and IFN­ were mediating 
their effects by acting on the same host cell compartment. We 
thus performed a similar set of experiments using chimeras 
with selective host cell IFN­ responsiveness. As expected, 
d38m2 tumor cells grew progressively in Rag2/, Ifngr1/, 
and Ifngr1/ → Ifngr1/ mice but were rejected in WT and 
WT → WT hosts (Fig. 2 C). Tumor growth was also observed 
in a significant fraction of Ifngr1/ → Rag2/ and WT → 
Ifngr1/ chimeras, though the defect in these mice (which 
selectively express the IFN­ receptor in either nonhemato­
poietic or hematopoietic cells, respectively) appeared less   
severe than that in globally insensitive Ifngr1/ → Ifngr1/  
chimeras. To ensure that tumor growth in the chimeric mice 
Figure 3.  IFN-/ sensitivity within the 
innate immune compartment is necessary 
and sufficient for tumor rejection. Mixed 
bone marrow chimeras with selective IFNAR1 
expression in innate or adaptive immune cells 
were generated by reconstitution of irradiated 
Ifnar1/ mice with mixtures of HSCs as de-
scribed in Results. (A) Splenocytes were isolated 
from representative cohorts of control and 
mixed chimeric mice at least 12 wk after re-
constitution, and IFNAR1 staining was ana-
lyzed by flow cytometry. Shown are the 
percentages of IFNAR1+ cells within the indi-
cated immune cell subsets for 8–14 mice of 
each type. Horizontal bars represent the mean. 
(B–D) Control WT, Rag2/, and Ifnar1/ mice 
and Ifnar1/ mixed chimeric mice were in-
jected with 106 H31m1 (B), d38m2 (C), or F515 
(D) tumor cells, and growth was monitored 
over time. Data are presented as mean tumor 
diameter ± SEM or the percentage or tumor-
positive mice per group from two to three 
independent experiments with group sizes as 
indicated. WT mice treated with control or IFN-– 
specific mAb were challenged with 106 F515 
tumor cells, and growth was monitored  
(D, bottom). Mean tumor diameter ± SEM for 7–10  
mice/group from two experiments is shown.JEM Vol. 208, No. 10 
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behavior of unedited MCA sarcoma cells (F515) that require 
lymphocytes and IFN­ but not host IFN­/ responsiveness 
for their rejection. F515 tumor cells grew progressively when 
injected into Rag2/ mice and WT mice treated with IFN­– 
specific H22 mAb but were rejected in WT mice, WT mice 
treated with isotype control PIP mAb, and Ifnar1/ hosts   
(Fig. 3 D). Similar to Ifnar1/ mice, F515 cells were also re­
jected  in  Ifnar1/  mixed  chimeras  of  each  type,  verifying 
functional reconstitution of the immune compartment. Third, 
to rule out a potential hyperactive immunological state in these 
reconstituted mice, we challenged Ifnar1/ mixed chimeras 
and control mice with MCA sarcoma cells derived from WT 
mice (1877). We have previously established that this tumor 
grows progressively when transplanted into naive WT mice 
(unpublished data). Similarly, these tumor cells grew progres­
sively in Ifnar1/ mixed chimeras of each type (Fig. 4 C).
Sensitivity to type I IFN in innate immune cells is required 
for the generation of tumor-specific CTL
To investigate the mechanism by which endogenous type I 
IFN promoted host antitumor responses, we looked specifi­
cally at the priming of tumor­specific T cells in WT and   
Ifnar1/ mice after tumor challenge. Splenocytes from WT 
hosts isolated 20 d after inoculation of H31m1 tumor cells 
showed robust cytolytic activity against H31m1 targets after 
in vitro restimulation (Fig. 5 A). In contrast, tumor­specific 
killing  was  largely  absent  from  splenocytes  derived  from   
Ifnar1/ mice challenged with tumor cells. Similar 
results were observed using another highly immuno­
genic unedited MCA sarcoma (GAR4.GR1) or 
using IFN­ production as a readout (unpublished 
data). To ask whether type I IFN sensitivity in in­
nate immune cells was sufficient to generate tumor­
specific immune responses, we used the mixed bone 
marrow  chimeras  described  previously  (Fig.  3). 
These experiments showed that IFN­/’s actions 
on the innate immune compartment were indeed 
both necessary and sufficient for development of   
adaptive  chimeras).  Control  chimeras  with  responsiveness   
in  both  innate  and  adaptive  compartments  (Rag2/  +   
WT → Ifnar1/; innate + adaptive) or neither compartment 
(Ifnar1/ → Ifnar1/; “neither”) were also generated. The 
phenotypes  of  mixed  chimeras  generated  using  this  ap­
proach were confirmed by IFNAR1 staining of splenocyte 
subsets (Fig. 3 A and Fig. S6).
When challenged with H31m1 or d38m2 cells, Rag2/ 
and Ifnar1/ control mice and globally unresponsive “nei­
ther” chimeras developed progressively growing tumors. In 
contrast, WT controls and pan­hematopoietic responsive in­
nate + adaptive or WT → WT chimeras rejected the tumor 
challenge (Fig. 3, B and C), consistent with our previous re­
sults (Fig. 2). Importantly, H31m1 and d38m2 cells were re­
jected in mixed chimeras with IFN­/ sensitivity only in 
innate immune cells (i.e., innate chimeras) but grew progres­
sively  in  chimeras  with  IFN­/  sensitivity  largely  re­
stricted to the adaptive immune compartment (i.e., adaptive 
chimeras). These findings demonstrate that the essential anti­
tumor functions of type I IFN on host cells during tumor   
rejection are selectively directed toward cells of the innate 
immune compartment.
To confirm the functional hematopoietic reconstitution 
of Ifnar1/ mixed chimeras, we performed three experi­
ments. First, we confirmed the normal representation of vari­
ous immune cell subsets within the spleens of mixed chimeric 
mice (Fig. 4, A and B). Second, we assessed the in vivo growth 
Figure 4.  Normal hematopoietic reconstitution in  
Ifnar1/ mixed bone marrow chimeras. (A) Spleens were 
harvested from WT, Ifnar1/, or Ifnar1/ mixed chimeras 
of each type (12 wk after reconstitution), and cell density 
was determined. Horizontal bars represent the mean.  
(B) Percentages of the indicated immune cell subsets were 
measured by flow cytometry for WT, Ifnar1/, and Ifnar1/ 
mixed chimeras. Mean values (as a percentage of total  
splenocytes) ± SEM for four to five mice/group are shown.  
Cell populations were defined as follows: CD4+ T cells 
(CD3+CD4+), CD8+ T cells (CD3+CD8+), B cells (B220+), NK cells 
(DX5+CD3), DCs (CD11chi), and myeloid cells (CD11b+).  
(C) WT-derived 1877 tumor cells were injected at a dose of 
106 cells/mouse into WT, Ifnar1/, Rag2/, and Ifnar1/ 
mixed chimeras, and tumor growth was monitored over 
time. Data represent the mean tumor diameter ± SEM for 
three to eight mice/group. (A–C) Data are representative of 
two independent experiments.1994 Type I IFN effects during tumor rejection | Diamond et al.
genetically  pure  C57BL/6  Rag2/  mice  and  naive  WT 
C57BL/6 mice as recipients because we could deplete NK 
cells in C57BL/6 mice with the NK1.1­specific PK136 mAb 
(Koo and Peppard, 1984). Similar to results with unedited 
MCA sarcomas from 129/Sv mice, immune­mediated rejec­
tion of two representative C57BL/6 strain unedited sarcomas 
(1969 and 7835) required IFN­/ sensitivity at the level of 
the host (Fig. 6, A and B). When PK136­treated WT mice 
were  injected  with  unedited  C57BL/6  tumor  cells,  they   
rejected these tumors with kinetics identical to control mice. 
We  confirmed  NK  cell  depletion  by  (a)  flow  cytometry,   
(b) the absence of ex vivo killing of YAC­1 targets by spleno­
cytes from mAb­treated mice, and (c) the lack of in vivo 
control of RMA­S tumor cell growth (Fig. 6, C–E). These 
data  therefore  indicate  that  NK1.1+  NK  cells  are  not   
required  for  IFN­/–dependent  rejection  of  unedited 
MCA sarcomas.
Granulocytes and macrophages do not require  
type I IFN sensitivity for tumor rejection
To test whether type I IFN sensitivity is required by granulo­
cytes  and  macrophages  for  tumor  rejection,  we  crossed 
C57BL/6 strain LysM-Cre+ mice (Clausen et al., 1999) to 
C57BL/6 Ifnar1f/f mice (Prinz et al., 2008; prepared by back­
crossing 129 strain Ifnar1f/f mice >99% onto a C57BL/6 back­
ground  using  a  speed  congenic  approach).  The  resulting 
LysM-Cre+Ifnar1f/f mice displayed complete IFNAR1 deletion 
in peritoneal macrophages and PMNs and substantial deletion 
of IFNAR1 in monocytes (66%) and splenic macrophages 
(35%) but maintained undiminished IFNAR1 expression in 
DCs, NK cells, T cells, and B cells (Fig. 7, A and B). Perito­
neal macrophages from these mice were unresponsive to type 
I IFN and failed to phosphorylate STAT1 after IFN­ stimula­
tion (Fig. 7 C). However, LysM-Cre+Ifnar1f/f mice still rejected 
highly immunogenic unedited B6 strain 1969 sarcoma cells 
similar to IFN­/–responsive Ifnar1f/f mice (Fig. 7 D). In 
contrast,  these  tumor  cells  formed  progressively  growing   
tumors in B6 strain Ifnar1/ control mice. Thus, protective 
tumor immunity does not require type I IFN sensitivity in 
granulocytes and at least some macrophage compartments.
CD8+ lineage DCs are important targets  
of type I IFN’s actions
Having ruled out NK cells, PMNs, and certain macrophage 
subsets as the critical type I IFN responsive cellular popula­
tions, we turned our attention to DCs. We previously showed 
that the selective absence of CD8+ lineage DCs in 129 strain 
Batf3/ mice led to an impairment in tumor­specific CTL 
priming and an inability to reject 129 strain H31m1 or 1773 
unedited  sarcoma  cells  (Hildner  et  al.,  2008).  We  sub­
sequently made similar observations using three other unedited 
129 strain sarcoma cell lines (d38m2, d42m1, and GAR4.
GR1) that require IFNAR1 in host cells for rejection (un­
published data). Given the effects of type I IFN in promoting 
DC maturation, we hypothesized that DCs, and specifically 
CD8+ lineage DCs, may be critical innate immune targets 
tumor­specific cytotoxicity (Fig. 5 B). In addition, treatment 
of splenocytes from innate chimeras with blocking CD4­ or 
CD8­specific antibodies confirmed the importance of CD8+ 
cells for in vitro cytotoxicity (Fig. 5 C). These results demon­
strate the selective importance of type I IFN on innate im­
mune cells to induce tumor­specific CTL priming.
NK cells are not required for type I IFN–dependent  
tumor rejection
Because NK cells have a host­protective function in some 
tumor models and display enhanced cytotoxic activity in re­
sponse to type I IFN, we investigated the role of NK cells   
in the rejection of highly immunogenic sarcomas. We used 
comparable  unedited  MCA  sarcoma  cells  generated  from   
Figure 5.  Impaired tumor-specific CTL priming in Ifnar1/ mice is 
restored by IFN-/–responsive innate immune cells. (A) Splenocytes 
from WT and Ifnar1/ mice were isolated 20 d after H31m1 tumor chal-
lenge (106 cells/mouse), co-cultured with IFN-–treated, irradiated 
H31m1 cells, and 5 d later used as effectors in a cytotoxicity assay with 
51Cr-labeled H31m1 targets. Specific killing activity (in percentage ± SEM) 
at the indicated effector/target (E:T) ratios is shown for four to five mice 
per group assayed in duplicate from three independent experiments.  
(B) Splenocytes were harvested from the indicated chimeric mice 20 d 
after injection of 106 H31m1 tumor cells and were treated as in A. Data 
include representative results from three mice per group assayed in dupli-
cate from two independent experiments. Splenocytes harvested from a 
naive mouse and treated similarly served as a negative control. (C) Effec-
tor cells from H31m1-challenged innate chimeras were co-cultured at the 
indicated effector/target ratios with 51Cr-labeled H31m1 targets in the 
presence of 10 µg/ml control (PIP), anti-CD4 (GK1.5), or anti-CD8 (YTS-
169.4) mAbs. Data show representative results from three mice per group 
assayed in duplicate from three independent experiments. Similar results 
were obtained when effector cells from H31m1-injected WT mice were 
used (not depicted). (B and C) Error bars represent SEM.JEM Vol. 208, No. 10 
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expression  corresponds  to  the  selective  expression  of  Cre   
recombinase in these cell types as indicated by expression of 
a bicistronic GFP gene that is contributed by the Itgax-Cre 
mouse (Fig. S8 B). Both CD8+ and CD4+ DCs from Itgax-
Cre+Ifnar1f/f mice exhibited significantly decreased respon­
siveness to type I IFN as detected by reduced accumulation 
of pSTAT1 (Fig. 8 C) and by impaired up­regulation of 
CD86 upon stimulation with IFN­ (Fig. S8 C). In contrast, 
T cells and macrophages in Itgax-Cre+Ifnar1f/f mice displayed 
type I IFN responsiveness that was comparable with cells 
from Ifnar1f/f mice. The selective nature of IFNAR1 deletion 
and loss of function in DCs allowed us to examine whether 
these cells were obligate targets of type I IFN during devel­
opment of antitumor responses in vivo. Whereas unedited 
B6 strain 1969 sarcoma cells were rejected in WT or Ifnar1f/f 
mice, they formed progressively growing tumors in Itgax-
Cre+Ifnar1f/f mice with growth kinetics indistinguishable from 
those in Ifnar1/ mice (Fig. 8 D). These results thus demon­
strate that type I IFN sensitivity is specifically required by 
DCs for development of host­protective tumor immunity.
Adoptive  transfer  of  type  I  IFN–responsive  DCs  into   
Ifnar1/ mice promotes induction of antitumor responses. 
Third, we examined whether the adoptive transfer of CD11c+ 
cells  isolated  from  the  spleens  of  naive  WT  or  Ifnar1/  
mice  into  Ifnar1/  recipients  promoted  tumor  resistance   
in  vivo. Whereas  CD11c+  cells  from WT  mice  induced   
of type I IFN during tumor rejection. The following four sets 
of experiments were performed to test this hypothesis.
DC subsets develop normally in the absence of IFNAR1. 
First, we assessed whether Ifnar1/ mice displayed a defi­
ciency in any DC populations. Analyses of splenic and LN 
cells revealed no difference between the numbers of each DC 
subset in WT and Ifnar1/ mice (Fig. S7). In addition, there 
was no defect in the ability of Ifnar1/ DCs to expand in 
vivo in response to flt3 (fms­like tyrosine kinase 3) ligand­Fc 
treatment (not depicted). Thus, the absence of type I IFN 
signaling did not affect the development of any DC subset.
IFN-/ signaling by DCs is required for rejection of 
tumors. Second, we assessed tumor rejection in mice that 
displayed a selective deletion of IFNAR1 in DCs. We crossed 
the aforementioned C57BL/6 strain Ifnar1f/f mice to a spe­
cific line of Itgax (CD11c)-Cre+ mice generated on a pure 
C57BL/6 genetic background (Stranges et al., 2007). When 
compared with the same cell populations from control mice 
by flow cytometry, IFNAR1 was expressed in undiminished 
levels in B cells, T cells, NK cells, macrophages, granulo­
cytes, and plasmacytoid DCs (pDCs) from Itgax-Cre+Ifnar1f/f 
mice (Fig. 8, A and B; and Fig. S8 A). In contrast, IFNAR1 
expression was substantially reduced in CD8+ DCs, the 
highly related CD103+ DCs, and CD4+ DCs from Itgax-Cre+ 
Ifnar1f/f mice (Fig. 8, A and B). The reduction in IFNAR1   
Figure 6.  NK cell depletion does not abro-
gate IFN-/–dependent rejection of immuno-
genic sarcomas. (A and B) C57BL/6 WT, Rag2/, 
and Ifnar1/ mice and WT mice treated with 
either PBS or anti-NK1.1 PK136 mAb were in-
jected s.c. (106 cells/mouse) with 1969 (A) or 7835 
(B) unedited MCA sarcoma cells, and growth was 
monitored over time. Data are presented as mean 
tumor diameter ± SEM of 4–13 (untreated) or 8 
(treated) mice per group from at least two inde-
pendent experiments. Error bars for Ifnar1/ 
mice reflect progressive growth of 1969 and 7835 
tumors in 6/9 mice. (C) WT C57BL/6 mice were 
treated with either PBS or PK136 mAb, and sple-
nocytes were harvested 2 d later and analyzed by 
flow cytometry using the NK cell markers DX5 
and NKp46. Splenocytes were gated on CD3 
cells, and the percentages of DX5+NKp46+ cells 
are indicated. Similar results were found when 
harvested at day 6 (not depicted). (D) WT C57BL/6 
mice were treated with PBS or PK136 followed by 
i.p. injection of 300 µg polyI:C 4 d later. After 24 h,  
splenocytes were harvested and used as effec-
tors in a standard 4-h cytotoxicity assay with  
NK-sensitive YAC-1 targets. Specific lysis  
(in percentage ± SEM) at the indicated effector/
target (E:T) ratios is shown for four mice/group 
assayed in duplicate from two independent  
experiments. (E) WT C57BL/6 mice were treated with PBS, PK136, or a mixture of anti-CD4 (GK1.5) and anti-CD8 (YTS-169.4) mAbs and injected s.c. with 
105 RMA-S cells, and tumor growth was monitored over time. Mean tumor diameter ± SEM for three mice/group is shown, and data are representative of 
two independent experiments.1996 Type I IFN effects during tumor rejection | Diamond et al.
from WT mice were more effective than Ifnar1/­derived 
cells in inducing the proliferation of OT­I T cells (Fig. 9 A), 
although  this  defect  could  be  overcome  at  high  doses  of 
antigen. Cross­presentation by WT CD11c+ cells was en­
hanced by treatment with exogenous IFN­ and inhibited 
by the addition of MAR1­5A3 mAb that blocked the type I 
IFN receptor on these cells (Fig. 9 B). When WT and   
Ifnar1/ DCs were further purified into CD8+ and CD4+ 
subsets, the CD8+ DC subset was shown to be the critical 
cross­presenting cell in this assay, and a more significant defi­
cit was observed in the capacity of Ifnar1/ CD8+ DCs to 
activate OT­I T cells (Fig. 9 C). Importantly, the CD8+ 
DCs from Itgax-Cre+Ifnar1f/f mice displayed an OVA antigen 
cross­presentation  defect  that  was  virtually  identical  to 
CD8+ DCs from Ifnar1/ mice (Fig. 10). Similar results 
were also obtained when MHC mismatched, IFN­–insensitive 
CMS­5­IC tumor target cells that were transduced with   
an OVA­expressing retrovirus were used   
as a source of antigen (Fig. S10). These 
findings  thus  demonstrate  that  type  I   
IFN acts directly on CD8+ DCs to en­
hance cross­presentation of antigen to 
naive CD8+ T cells.
tumor­specific CTL priming (Fig. S9 A), Ifnar1/ CD11c+ 
cells did not. The transfer of WT CD11c+ cells also delayed 
tumor growth but did not result in tumor rejection (Fig. S9 B). 
In contrast, no effect on tumor growth was observed upon 
transfer of CD11c+ cells derived from Ifnar1/ mice. This 
difference was statistically significant (P = 0.03). These results 
are consistent with our previous observation that transfer of 
purified DC populations into Batf3/ mice results in only 
partial reconstitution of the antitumor response, perhaps be­
cause of issues of DC trafficking (Hildner et al., 2008).
Type  I  IFN  enhances  the  cross-presenting  activity  of 
CD8+ lineage DCs. Fourth, we assessed whether type I IFN   
directly affected antigen cross­presentation by DCs in vitro 
by culturing splenic DCs isolated from WT or Ifnar1/ 
mice with irradiated ovalbumin­loaded MHC class I–deficient 
splenocytes and OT­I T cells. Total CD11c+ cells purified 
Figure 7.  Granulocytes and macrophages do 
not require type I IFN sensitivity for tumor 
rejection. (A) IFNAR1 expression on peritoneal 
macrophages, blood monocytes, PMNs, and  
B cells was measured using flow cytometry in 
Ifnar1f/f, LysM-Cre+Ifnar1f/f, and Ifnar1/ mice.  
(B) Summary of IFNAR1 levels in the indicated 
cellular subsets in LysM-Cre+Ifnar1f/f mice com-
pared with Ifnar1f/f mice (expressed as a percent-
age of the mean fluorescence intensity [MFI]). 
Cells were gated using the following markers: 
macrophages (CD11b+F4/80+), PMNs (CD11b+ 
Gr1+), monocytes (CD115+CD11b+), B cells 
(B220+), CD8+ DCs (CD8+Dec205+CD11chi), 
CD4+ DCs (CD8Dec205CD11chiCD4+), pDCs 
(B220+PDCA+CD11cint), T cells (CD3+), and NK cells 
(NK1.1+). IFNAR1 expression was measured using 
MAR1-5A3 mAb. Data represent at least three 
mice from three independent experiments (**, P < 
0.01). (C) Mature peritoneal macrophages from 
LysM-Cre+Ifnar1f/f mice were untreated (gray) or 
stimulated for 15 min with 10 ng/ml IFN-v4 
(black), and pSTAT1 accumulation was measured 
by flow cytometry. Histograms from a represen-
tative experiment are shown, with the bar graph 
summarizing pSTAT1 levels (as percentage of 
control Ifnar1f/f MFI) from two independent ex-
periments. (B and C) Error bars represent SEM.  
(D) Ifnar1f/f, LysM-Cre+Ifnar1f/f, and Ifnar1/ 
mice were injected s.c. with 106 1969 unedited 
sarcoma cells. Mean tumor diameter ± SEM from 
a representative experiment is shown, and the bar 
graph shows the percentage of tumor-positive 
mice per group from two independent experi-
ments with indicated total group sizes.JEM Vol. 208, No. 10 
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IFN during tumor rejection are distinguishable from those   
of IFN­ both temporally and functionally, and they repre­
sent an important step toward mapping the critical molecular 
pathways involved in cancer immunoediting.
Functionally active type I IFN receptors are expressed on 
nearly all nucleated cells, and previous studies documented 
effects of type I IFN on many immunologically relevant cell 
types (such as T cells, NK cells, and DCs) that theoretically 
should enhance the immune elimination of tumors (Dunn   
et al., 2006). Thus, it was surprising to find an essential func­
tional requirement for type I IFN in only a single cellular 
compartment, namely DCs, during the development of pro­
tective tumor­specific immune responses in vivo. As further 
documented in vitro, type I IFN enhances the function of 
the CD8+ DC subset, which in a previous study was shown 
to play a critical role in the development of tumor­ and virus­
specific immune responses through its capacity to cross­present 
antigen to CD8+ T cells (Hildner et al., 2008). These cells, 
DISCUSSION
Previous work from our laboratory and others has shown that 
naturally occurring, host­protective immune responses against 
many highly immunogenic tumors require the obligate par­
ticipation of endogenously produced type I IFN (Dunn et al., 
2005;  Swann  et  al.,  2007).  Although  these  earlier  studies 
pointed to hematopoietic cells as the physiologically relevant 
targets of type I IFN action, they neither identified the spe­
cific cell populations affected nor defined the functions that 
they performed. The current study was undertaken to eluci­
date the role of endogenously produced type I IFN in driving 
host­protective, antitumor responses. Herein we demonstrate 
that type I IFN exerts its activity early during the develop­
ment of the antitumor response, that its major physiological 
function is directed selectively toward a single host cell popu­
lation (i.e., DCs), and that, at least in part, it functions to en­
hance the capacity of CD8+ DCs to cross­present antigen to 
CD8+ T cells. These data thus reveal that the actions of type I   
Figure 8.  DCs specifically require type I IFN 
sensitivity for tumor immunity in vivo.  
(A) IFNAR1 expression on splenic CD8+ DCs, 
CD4+ DCs, pDCs, LN CD103+ DCs, and dermal DCs 
was measured using flow cytometry in Ifnar1f/f, 
Itgax-Cre+Ifnar1f/f, and Ifnar1/ mice. (B) Sum-
mary of IFNAR1 levels on the indicated cellular 
subsets in Itgax-Cre+Ifnar1f/f mice compared with 
Ifnar1f/f mice (expressed as a percentage of control 
mean fluorescence intensity [MFI]). Cells were gated 
as follows: CD8+ DCs (CD8+Dec205+CD11chi), 
CD103 DCs (CD8Dec205+CD11chiCD103+),  
CD4+ DCs (CD8Dec205CD11chiCD4+),  
dermal DCs (CD8CD11chiCD103), pDCs 
(B220+PDCA+CD11cint), B cells (B220+),  
T cells (CD3+), NK cells (NK1.1+), macrophages 
(CD11b+F4/80+), and blood PMNs (CD11b+Gr1+). 
IFNAR1 expression was measured using the 
MAR1-5A3 mAb. Data represent three to five 
mice from at least three independent experi-
ments. (**, P < 0.01). (C) Splenocytes from Itgax-
Cre+Ifnar1f/f mice were untreated (gray) or 
stimulated for 15 min with 10 ng/ml IFN-v4 
(black), and pSTAT1 accumulation in CD8+ and 
CD4+ DCs was measured by flow cytometry. His-
tograms show a representative experiment, and 
the bar graph summarizes results from four inde-
pendent experiments (**, P < 0.01). (B and C) Error 
bars represent SEM. (D) C57BL/6 WT, Ifnar1/, 
Ifnar1f/f, and Itgax-Cre+Ifnar1f/f mice were in-
jected s.c. with 106 1969 unedited sarcoma cells. 
Mean tumor diameter ± SEM from a representa-
tive experiment is shown, and the bar graph 
shows a summary of the percentage of tumor-
positive mice per group from three independent 
experiments with indicated groups sizes (P < 
0.001 [WT vs. Ifnar1/] and P < 0.001 [Ifnar1f/f 
vs. Itgax-Cre+Ifnar1f/f]) using the Student’s t test 
at day 23. Comparisons of Ifnar1/ versus Itgax-
Cre+Ifnar1f/f or WT versus Ifnar1f/f were not sig-
nificantly different.1998 Type I IFN effects during tumor rejection | Diamond et al.
Support for this conclusion comes directly from the find­
ing that bone marrow chimeric mice with selective recon­
stitution of type I IFN sensitivity in the innate immune 
compartment  generated  tumor­specific  CTL  and  rejected 
immunogenic tumor cells, whereas the direct actions of type 
I IFN on T and B lymphocytes contributed little to the anti­
tumor response. It is important to stress that whereas the re­
sults of our analyses clearly show that T cells are not the 
essential type I IFN–sensitive cellular population, immune 
elimination  of  tumors  nevertheless  requires  both  CD4+  
and CD8+ T cells. The lack of a requirement for type I IFN   
responsiveness  in  T  lymphocytes  contrasts  with  results   
from studies of CD8+ T cell priming and clonal expansion   
in the settings of  viral infection or  protein immunization 
which are dependent on the BATF3 transcription factor for 
their development, were originally identified as the CD8+ 
DCs that resided in lymphoid organs; yet subsequent work 
showed that they are closely related to another small DC subset 
residing  in  peripheral  tissues  that  lack  CD8  but  express 
CD103 (Hildner et al., 2008; Ginhoux et al., 2009; Edelson 
et al., 2010). Although we find herein that optimal cross­ 
presenting activity of CD8+ DCs occurs only in response to 
type I IFN, our results do not exclude a requirement for type 
I IFN in regulating other DC populations such as CD4+ DCs. 
Thus, we conclude that the CD8+ DC subset represents 
one innate immune cell population that displays an obligate 
requirement for type I IFN to perform its function in the anti­
tumor response.
Figure 9.  Type I IFN sensitivity in CD8+ DCs enhances antigen cross-presentation. (A) CD11c+ cells were isolated from the spleens of WT or 
Ifnar1/ mice and co-cultured with the indicated number of irradiated, ovalbumin-loaded MHC class I/ splenocytes and CFSE-labeled OT-I T cells. 
After a 3-d incubation, proliferation of OT-I T cells was determined by CSFE dilution. Histograms represent CFSE levels in the CD8+ T cell population, with 
the percentage of cells in the indicated gate noted. (B) WT and Ifnar1/ CD11c+ cells or WT CD11c+ cells incubated with exogenous 1,000 U/ml IFN- or 
5 µg/ml IFNAR1-specific MAR1-5A3 mAb were treated as in A at a dose of 25,000 MHC class I/ splenocytes. (C) Purified CD8+ and CD4+ DC subsets 
isolated from WT or Ifnar1/ mice were treated as in A with the indicated number of ovalbumin-loaded MHC class I/ splenocytes. Data represent one 
of at least two independent experiments with similar results.
Figure 10.  Impaired antigen cross-presentation in 
CD8+ DCs from Itgax-Cre+Ifnar1f/f mice. CD8+ DCs 
were isolated from Ifnar1f/f, Itgax-Cre+Ifnar1f/f, and Ifnar1/ 
mice and incubated with OT-I T cells labeled with cell prolif-
eration dye and 12,500 ovalbumin-loaded MHC class I/ 
splenocytes. Dilution of the cell proliferation dye was  
measured 3 d later. Data represent one of at least two 
independent experiments with similar results.JEM Vol. 208, No. 10 
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we focused our attention on DCs as likely innate immune 
targets of type I IFN’s actions. Although type I IFN is a strong 
inducer of DC maturation (Luft et al., 1998; Gallucci et al., 
1999; Montoya et al., 2002), the specific role of this cellular 
subset in the generation of protective antitumor responses has 
been difficult to establish. Some studies have indeed impli­
cated bone marrow–derived cells in the cross­presentation   
of tumor­associated antigen (Huang et al., 1994), whereas 
others have argued that direct priming may additionally be 
involved (Ochsenbein et al., 2001; Wolkers et al., 2001). 
Moreover, although the CD8+ DC subset is particularly   
adept at antigen cross­presentation, evidence also exists that 
other non­DC immune subsets as well as nonhematopoietic 
stromal cells might be capable of cross­presenting exogenous 
antigen  in  some  circumstances  (Ackerman  and  Cresswell, 
2004; Heath et al., 2004; Spiotto et al., 2004).
The generation of mice lacking the transcription factor 
BATF3  provided  a  useful  mechanism  to  study  DC  cross­ 
presentation in vivo because these mice have a cell­intrinsic 
defect in the development of CD8+ DCs but normal repre­
sentation and function of the remaining DC subsets as well as 
other hematopoietic lineages (Hildner et al., 2008). Highly 
immunogenic MCA sarcoma cells, which are rejected in WT 
mice, formed progressively growing tumors in Batf3/ mice 
and displayed growth kinetics comparable with those in lym­
phocyte­deficient Rag2/ hosts (Hildner et al., 2008), a re­
sult which we have corroborated in the current study. In 
addition, the defect in Batf3/ mice correlated with a lack of 
tumor­specific CTL priming (Hildner et al., 2008). These 
findings therefore demonstrated that cross­priming by CD8+ 
lineage DCs is critical for tumor rejection, although they do 
not address the nature of the innate immune signals necessary 
for activation, migration, and in vivo function of these cells. 
The  importance  of  such  stimuli  is  clear  because  cross­ 
presentation without activation can lead to tolerance rather than 
immunity  (Steinman  et  al.,  2003;  Melief,  2008).  A  better   
understanding of this process could provide insight into the 
mechanisms that progressively growing tumors use to escape 
immune control.
We show in this study that type I IFN enhances the cross­
presentation of cell­associated antigen to naive CD8+ T cells 
via direct actions on CD8+ lineage DCs. When taken to­
gether with data demonstrating that (a) type I IFN promotes 
tumor­specific CTL priming, (b) type I IFN acts on innate 
immune cells to mediate its antitumor effects, (c) IFN­/–
responsive CD11c+ cells partially reconstitute in vivo CTL 
priming in Ifnar1/ mice, (d) CD8+ lineage DCs are re­
quired for CTL priming and tumor rejection, and (e) selective 
deletion of IFNAR1 in DCs abrogates tumor rejection, the 
collective evidence supports a host­protective function involv­
ing direct actions of type I IFN on CD8+ lineage DCs.
The mechanism responsible for type I IFN’s enhancement 
of CD8+ DC cross­priming remains to be determined. Type 
I IFN may induce multiple effects on the CD8+ lineage DCs, 
including the modulation of antigen capture or processing, 
peptide shuttling and MHC loading, MHC class I and/or 
(Kolumam et al., 2005; Le Bon et al., 2006a). Yet, it was 
noted in these studies that during infection­induced clonal 
expansion, the relative importance of type I IFN’s actions on 
CD8+ T cells depended on the specific microbial pathogen 
used (Thompson et al., 2006), with T cell expansion during 
lymphocytic  choriomeningitis  virus  infection  showing  a   
profound dependence on type I IFN, but less prominent im­
pairments occurring when other viruses were used. In addi­
tion, another study reported no change in the generation of 
antigen­specific CTL in mice lacking the type I IFN receptor 
in the T cell compartment after immunization with peptide 
and IC31 (Pilz et al., 2009), an adjuvant based on Toll­like 
receptor 9 signaling. Given these data, it was suggested that 
distinct inflammatory environments might evoke expansion 
of CD8+ T cell subsets that differ in their dependence on 
type I IFN for survival and function and that such environ­
mental cues may include the levels of type I IFN and other 
signals that stem from innate cells (Stetson and Medzhitov, 
2006; Thompson et al., 2006). Little is known about the 
magnitude and localization of type I IFN production (and 
that of other inflammatory cytokines) during immune re­
sponses to tumors, and further investigation is warranted.
To further define the target cells within the innate im­
mune compartment affected by type I IFN, we bred Ifnar1f/f 
mice to LysM-Cre mice, an accepted method of deleting 
floxed target genes in non­DC myeloid cells (Clausen et al., 
1999). The resulting mice exhibited nearly complete deletion 
of IFNAR1 in peritoneal macrophages and PMNs and re­
duced levels of IFNAR1 in other myeloid populations in­
cluding monocytes and splenic macrophages. Nevertheless, 
targeting myeloid cell IFNAR1 to the levels observed did not 
compromise antitumor immunity. These findings exclude a 
prominent role for granulocyte type I IFN sensitivity in our 
tumor system contrasting with data in the B16 melanoma 
model, suggesting that direct effects of endogenous IFN­ 
on tumor­infiltrating neutrophils are responsible for its anti­
tumor functions by suppressing expression of proangiogenic 
factors (Jablonska et al., 2010). With respect to the contribu­
tions of monocyte/macrophage subsets, more work is needed 
to define whether specific populations contribute to tumor 
immunity in the MCA sarcoma model, whether they are the 
same populations targeted in the LysM-Cre mouse, and which 
functions, if any, are influenced by type I IFN. Others have 
nonetheless  shown  that  LysM-Cre+Ifnar1f/f  mice  exhibit  a 
clear phenotype during experimental autoimmune encepha­
lomyelitis despite observing similar partial reductions of   
IFNAR1  in  myeloid  populations  (Prinz  et  al.,  2008).   
LysM-Cre+Ifnar1f/f mice display undiminished IFNAR1 ex­
pression in DCs. Thus, LysM-Cre+Ifnar1f/f mice also serve as 
a control to support the conclusion that IFNAR1 is required 
predominantly in DCs and that tumor immunity remains in­
tact when IFNAR1 is genetically deleted in non­DC innate 
immune compartments.
Given the findings that adaptive immune cells, granulo­
cytes, and macrophages function independently of type I IFN 
and that NK cells do not play an obligate role in our system, 2000 Type I IFN effects during tumor rejection | Diamond et al.
MATERIALS AND METHODS
Mice. 129/SvPas WT mice were purchased from Charles River. 129/SvEv 
Rag2/, C57BL/6 WT, and C57BL/6 Rag2/ mice were obtained from 
Taconic. C57BL/6 strain Itgax-Cre+/ (GFP) mice (Stranges et al., 2007) and 
LysM-Cre+/ mice (Clausen et al., 1999) were obtained from the Jackson 
Laboratory. 129/Sv strain Ifnar1/ and Ifngr1/ were as described previ­
ously  (Dunn  et  al.,  2005).  Ifnar1f/f  mice  were  as  described  previously   
(Kamphuis et al., 2006). Both Ifnar1f/f and Ifnar1/ mice were backcrossed 
onto the C57BL/6 background by speed congenic analysis (>99.7% purity). 
129/Sv Rag2/Ifnar1/ mice were generated by intercrossing Rag2/ 
and Ifnar1/ mice. OT­I transgenic mice on a Rag1/ background were 
obtained through the National Institute of Allergy and Infectious Diseases 
Exchange  Program,  National  Institutes  of  Health  (C57BL6­Tg(OT-I)-
RAG1tm1Mom  004175;  Mombaerts  et  al.,  1992;  Hogquist  et  al.,  1994). 
C57BL/6 MHC class I–deficient Kb/Db/2m/ mice (Lybarger et al., 
2003) were a gift from H. Virgin and T. Hansen (Washington University in 
St. Louis, St. Louis, MO). 129/SvEv background Batf3/ mice have been 
described previously (Hildner et al., 2008). Mice were maintained in a spe­
cific pathogen­free facility in accordance with American Association for 
Laboratory Animal Science guidelines, and all protocols involving laboratory 
animals were approved by the Washington University Animal Studies Com­
mittee (School of Medicine, Washington University in St. Louis).
Tumor transplantation. MCA­induced fibrosarcomas were derived from 
129/Sv strain Rag2/ or WT mice and C57BL/6 strain Rag2/ mice as de­
scribed previously (Shankaran et al., 2001; Dunn et al., 2005; Koebel et al., 
2007). The GAR4 tumor, derived from an MCA­treated 129/Sv Ifngr1/ 
Ifnar1/ mouse, as well as IFNGR1­resconstituted GAR4.GR1 cells and 
IFNAR1­reconstituted  GAR4.AR1  cells  have  been  described  previously 
(Dunn et al., 2005). RMA­S is an MHC class I–deficient variant of the 
C57BL/6 strain T lymphoma RMA (Kärre et al., 1986). Tumor cells were 
propagated in vitro and injected s.c. in a volume of 150 µl endotoxin­free PBS 
into the shaved flanks of recipient mice as described previously (Dunn et al., 
2005). Injected cells were >90% viable as assessed by trypan blue exclusion. 
Tumor size was measured on the indicated days and is presented as the mean 
of two perpendicular diameters. When calculating percent tumor growth, 
mice with tumors >6 mm in diameter were considered positive.
Antibody treatment. For IFN­/ receptor blockade, mice were injected 
i.p.  with  a  single  2.5­mg  dose  of  IFNAR1­specific  MAR1­5A3  mAb   
(Sheehan et al., 2006) or GIR­208 isotype control mAb as described previ­
ously (Dunn et al., 2005). For IFN­ neutralization, 750 µg of IFN­– 
specific H22 mAb (Schreiber et al., 1985) or PIP isotype control mAb was 
injected i.p. followed by a 250­µg dose every 7 d. Broad immunodepletion 
was achieved by i.p. administration of a mixture of anti­CD4 GK1.5 mAb 
(Dialynas et al., 1983), anti­CD8 YTS­169.4 mAb (Cobbold et al., 1984), 
and IFN­–specific H22 mAb. For this regimen, an initial dose of 750 µg of 
each mAb or of the control PIP mAb was followed by 250 µg of each every 
7 d as described previously (Koebel et al., 2007). NK cell depletion was 
achieved in C57BL/6 mice by i.p. injection of 200 µg anti­NK1.1 PK136 mAb 
(Koo and Peppard, 1984; BioLegend) on days 2, 0, and 2 (relative to tumor 
injection) and 100 µg every 5 d.
Generation of bone marrow chimeras. Recipient mice were irradiated 
with a single dose of 9.5 Gy and reconstituted with donor HSCs isolated 
from embryonic day (E) 14.5 fetal livers or 5­fluorouracil (5­FU)–treated 
adult bone marrow as described previously (Christensen et al., 2004; Dunn 
et al., 2005). For harvest of fetal liver cells (FLCs), embryos were extracted 
at E14.5, livers were removed, washed in sterile endotoxin­free PBS, and 
homogenized through a cell strainer using a syringe plunger. 5­FU–treated 
bone  marrow  was  isolated  4–5  d  after  treatment  of  donor  mice  with   
150 mg/kg 5­FU by i.p. injection. Cells were injected i.v. at a dose of 5 × 106 
(FLCs) or 106 (5­FU–treated bone marrow) cells/mouse in 200 µl PBS.   
Total cell dose was determined by titration of FLCs (Fig. S3) or based on prior 
data (Dunn et al., 2005). For mixed chimeras, a 4:1 cell ratio was selected 
co­stimulatory molecule expression, cellular migration, sur­
vival, or the induction of secondary cytokines/chemokines. 
Although current understanding of the cell biology of cross­
presentation is incomplete, some data indicate that heightened 
or altered antigen processing, rather than better antigen cap­
ture, underlies the ability of the CD8+ DCs to efficiently 
cross­present antigen (Dudziak et al., 2007; Melief, 2008). Inter­
estingly, a recent study suggested that steady­state produc­
tion of low levels of IFN­ promotes antigen presentation by 
DCs to both CD8+ and CD4+ T cells via up­regulation of heat 
shock protein 70, which boosts formation of MHC–peptide 
complexes (Zietara et al., 2009). Another recent study dem­
onstrated that type I IFN contributes to cross­presentation   
by enhancing antigen retention and survival of CD8+ DCs 
(Lorenzi et al., 2011). Additional mechanisms must be in­
volved because baseline antigen presentation (in the presence 
of low­level IFN­) induces cross­tolerance in the absence of 
DC activation triggered by inflammatory signals such as en­
hanced type I IFN production (Melief, 2008). The presence 
of other inflammatory stimuli, which may collaborate with 
type I IFN to activate CD8+ DCs, is suggested by detection 
of residual low­level priming in the absence of type I IFN   
signaling and the somewhat more robust tumor growth   
in Batf3/ mice (lacking CD8+ DCs) compared with   
Ifnar1/ mice (containing normal numbers of type I IFN–
unresponsive CD8+ DCs). The involvement of other in­
flammatory stimuli and their influence on type I IFN’s 
effects remain to be investigated.
Exogenous  administration  of  recombinant  IFN­  has 
shown efficacy in the treatment of human cancer patients 
(Belardelli et al., 2002). However, despite many years of clin­
ical use, surprisingly little is known regarding its mechanism 
of action in this setting and the reason IFN­ treatment is   
effective in only a subset of patients. A host immunostimu­
latory mechanism is likely given the correlation between 
favorable responses to systemic IFN­ and the appearance   
of  autoimmune  sequelae  in  metastatic  melanoma  patients 
(Gogas et al., 2006). Animal studies have also confirmed that type 
I IFN activity on host cells, rather than actions on the tumor, 
mediate  the  protective  effect  of  IFN­/  administration 
(Belardelli et al., 2002). Whereas current treatments generally 
involve systemic injection of high­dose IFN­, it is possible 
that more targeted therapy based on a better understanding of 
the relevant underlying mechanism of action of type I IFN 
will enhance therapeutic efficacy while reducing undesirable 
side effects.
In summary, the findings made herein reveal that DCs 
represent the major targets of type I IFN actions during the 
induction of spontaneous tumor­specific CD8+ T cell re­
sponses and that these responses result, at least in part, from 
an enhanced capacity of CD8+ DCs to cross­present anti­
gen to CD8+ T cells. These findings provide a strong ratio­
nale for future studies aimed at elucidating the precise DC 
functions that are regulated by type I IFN that ultimately 
promote development of naturally occurring or therapeutic 
immune responses to cancer.JEM Vol. 208, No. 10 
Article
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Thy1.2, DX5, and CD8 negative selection, followed by CD4 positive se­
lection. In all cases, purity of the population of interest was >97%. Spleno­
cytes from Kb/Db/2m/ mice were prepared in serum­free medium, 
loaded with 10 mg/ml ovalbumin (EMD) by osmotic shock, and irradiated 
(13.5 Gy) as described previously (Hildner et al., 2008). OT­I T cells were 
purified from OT­I/Rag1/ mice by CD11c and DX5 negative selection 
followed by positive selection with CD8 microbeads (purity >99%). T cells 
were fluorescently labeled by incubation with 1 µM CFSE (Sigma­Aldrich) 
for 9 min at 25°C at a density of 2 × 107 cells/ml. For the assay, 5 × 104 puri­
fied DCs were incubated with 5 × 104 CFSE­labeled OT­I T cells in the 
presence of varying numbers of irradiated, ovalbumin­loaded Kb/Db/ 
2m/ splenocytes. In some assays, the irradiated target cells were mis­
matched (BALB/c) tumor cells expressing a truncated version of the IFN­ 
receptor to render them IFN­ insensitive and in which ovalbumin was 
retrovirally enforced (CMS­5­IC). Ovalbumin expression was confirmed 
by coexpression of GFP by flow cytometry and by Western blot using a 
mouse antiovalbumin mAb (Santa Cruz Biotechnology, Inc.). After 3 d, 
cells were stained with anti­CD8­APC and CFSE, or cell proliferation dye 
(eBioscience) dilution was measured by flow cytometry. For IFN­ treat­
ment, recombinant mouse IFN­5 (a gift from D. Fremont, Washington 
University in St. Louis) was added at 1,000 U/ml, whereas IFN­/ recep­
tor blockade was achieved by incubation with 5 µg/ml IFNAR1­specific 
MAR1­5A3 mAb.
Online  supplemental  material.  Fig.  S1  shows  the  kinetics  of  tumor 
growth in mice treated with blocking IFNAR1­specific mAb. Fig. S2 
demonstrates  the  importance  of  host  IFN­  sensitivity  for  rejection  of 
unedited sarcomas. Fig. S3 presents a titration of FLCs for generation of 
bone marrow chimeras. Figs. S4 and S5 show the normal functional im­
mune reconstitution of Ifngr1/ bone marrow chimeras (Fig. S4) and the 
absence of radio­resistant, tissue­resident leukocytes in the tumors of these 
mice (Fig. S5). Fig. S6 shows a determination of the HSC mixing ratio 
used to generate mixed bone marrow chimeras. Fig. S7 shows an analysis of 
DC subsets in Ifnar1/ mice. Fig. S8 shows further characterization of the   
Itgax-Cre+Ifnar1f/f mice. Fig. S9 shows adoptive transfer experiments of WT 
and Ifnar1/ CD11c+ cells into Ifnar1/ recipient mice. Fig. S10 shows 
decreased cross­presentation by CD8+ DCs from Itgax-Cre+Ifnar1f/f mice 
compared with Ifnar1f/f mice using retrovirally transduced tumor cells as a 
source of antigen. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20101158/DC1.
We are grateful to Tiffany Stephans for excellent technical assistance, to Dr. Emil 
Unanue for providing flt3 ligand-Fc, and to all members of the Schreiber laboratory 
for helpful discussions and assistance.
This work was supported by grants from the National Cancer Institute, 
National Institute of Allergy and Infectious Diseases (NIAID; Midwest Regional 
Center of Excellence), National Institute of Arthritis and Musculoskeletal and Skin 
Disease (Rheumatic Disease Core Centers), the Cancer Research Institute, and the 
Ludwig Institute for Cancer Research to R.D. Schreiber and from NIAID to  
K.M. Murphy. M. Kinder is supported by an Irvington Institute Postdoctoral 
fellowship from the Cancer Research Institute.
The authors have no conflicting financial interests.
Submitted: 10 June 2010
Accepted: 2 August 2011
REFERENCES
Ackerman, A.L., and P. Cresswell. 2004. Cellular mechanisms governing 
cross­presentation  of  exogenous  antigens.  Nat.  Immunol.  5:678–684. 
http://dx.doi.org/10.1038/ni1082
Belardelli, F., M. Ferrantini, E. Proietti, and J.M. Kirkwood. 2002. Interferon­
alpha in tumor immunity and immunotherapy. Cytokine Growth Factor 
Rev. 13:119–134. http://dx.doi.org/10.1016/S1359­6101(01)00022­3
Biron, C.A., K.B. Nguyen, G.C. Pien, L.P. Cousens, and T.P. Salazar­
Mather.  1999.  Natural  killer  cells  in  antiviral  defense:  function  and   
regulation by innate cytokines. Annu. Rev. Immunol. 17:189–220. http:// 
dx.doi.org/10.1146/annurev.immunol.17.1.189
based on testing of different mixing ratios (Fig. S6). Animals were main­
tained on trimethoprim­sulfamethoxazole (Hi­Tech Pharmacal) antibiotic 
water prepared as described previously (Dunn et al., 2005) for 4 wk after   
irradiation, and tumor transplantation of chimeric mice was performed at least 
12 wk after reconstitution. Hematopoietic reconstitution of all animals was 
verified by FACS staining of splenocytes at the completion of tumor trans­
plantation experiments. Similar experimental results were obtained with mice 
reconstituted using FLCs or 5­FU–treated bone marrow as donor cells.
Flow cytometry. Surface staining of single cell suspensions of splenocytes or 
tumor cells was performed using standard protocols and analyzed on a FACS­
Calibur (BD). Data analysis was conducted using FlowJo software (Tree Star). 
The following were obtained from BioLegend: anti­CD3­FITC (145­2C11), 
anti­CD4­PE (RMA4­5), anti­CD4­APC (GK1.5), anti–CD8­APC (53­
6.7), anti­CD8­FITC (53­6.7), anti­B220­FITC (RA3­6B2), anti­CD11b­
PE (M1/70), anti­CD11b­PerCP­Cy5.5 (and Pe­Cy7; M1/70), anti­DX5­PE 
(DX5),  anti­DX5­APC  (DX5),  anti–Gr­1–FITC  (RB6­8C5),  anti­ 
CD45­FITC (30­F11), anti­CD31­PE (MEC13.3), anti­CD24­FITC (M1/69), 
anti­CD103­PerCp­Cy5.5  (2E7),  anti­Dec205­Pe­Cy7  (NLDC­145),  anti­
F4/80­PerCP­Cy5.5 (BM8), anti­CD11c­APC­Cy7 (N418), and SA­APC. 
Anti­CD11c­PE (HL3), anti­CD8­PerCP­Cy5.5 (53–6.7), and anti­ 
IFNGR1­biotin (GR20) were obtained from BD, anti­NKp46­PE (29A1.4) 
was purchased from eBioscience, and anti­IFNAR1­biotin (MAR1­5A3) was 
described previously (Sheehan et al., 2006). For pSTAT1 assays, splenocytes 
were stained for cell surface markers before stimulation with 10 ng/ml IFN­v4 
for 15 min. Cells were then fixed with 2% paraformaldehyde, permeabilized 
with 90% methanol, and stained for pSTAT1 (BD). For CD86 expression, cells 
were cultured for 18 h with 10 ng/ml IFN­v4 before staining for cell surface 
markers and CD86­PE (BD).
Tumor-specific CTL killing assay. Spleens were harvested from mice   
20 d after tumor implantation, and single cell suspensions were prepared by 
homogenization using frosted glass slides. 4 × 107 splenocytes were cultured 
with 2 × 106 IFN­–treated, irradiated (100 Gy) tumor cells. 5 d later, the 
cells were harvested and used as CTL effector cells in a standard 4­h  51 
Cr­release cytotoxicity assay that used tumor cell targets seeded at 10,000   
cells/well and pretreated with 100 U/ml IFN­ for 48 h. For blocking   
assays, 10 µg/ml anti­CD8 (YTS­169.4), anti­CD4 (GK1.5), or control mAb 
(PIP) was added to the cell culture of effector and target cells. Percent spe­
cific killing was defined as (experimental condition cpm  spontaneous 
cpm)/(maximal (detergent) cpm  spontaneous cpm) × 100.
NK cell cytotoxicity assay. Splenocytes were isolated from mice treated 
with 300 µg polyI:C (Sigma­Aldrich) by i.p. injection 24 h prior and were 
used as effector cells with 5,000 51Cr­labeled YAC­1 tumor targets. Percent 
specific killing was assessed after 4­h coincubation. Each sample was assayed 
in duplicate, and experiments were performed at least twice.
Adoptive transfer of CD11c+ cells. Splenic CD11c+ cells from naive WT 
and Ifnar1/ mice (10 mice/group) were positively selected by MACS   
(purity >90%) using CD11c microbeads (Miltenyi Biotec). 2 × 106 CD11c+  
cells were mixed with 2 × 105 unedited MCA sarcoma cells (GAR4.GR1) 
in endotoxin­free PBS and injected s.c. in a volume of 200 µl into the flanks 
of Ifnar1/ mice at day 0. 3 d later, 2 × 106 CD11c+ cells were injected s.c. 
around the site of tumor implantation.
Antigen cross-presentation assay. DC cross­presentation of antigen to 
CD8+ OT­I T cells was assessed as previously described (Hildner et al., 
2008). In brief, spleens from naive WT or Ifnar1/ mice were digested with 
collagenase B (Roche) and DNase I (Sigma­Aldrich), and cellular subpopu­
lations were isolated by MACS purification (Miltenyi Biotec). Total CD11c+ 
DCs were obtained by negative selection using B220, Thy1.2, and DX5 micro­
beads followed by positive selection with CD11c microbeads. CD8+ DCs 
were recovered by B220, Thy1.2, DX5, and CD4 negative selection, fol­
lowed  by  CD8  positive  selection.  CD4+  DCs  were  isolated  by  B220, 2002 Type I IFN effects during tumor rejection | Diamond et al.
Hildner, K., B.T. Edelson, W.E. Purtha, M. Diamond, H. Matsushita, M. 
Kohyama, B. Calderon, B.U. Schraml, E.R. Unanue, M.S. Diamond, 
et  al.  2008.  Batf3  deficiency  reveals  a  critical  role  for  CD8alpha+ 
dendritic cells in cytotoxic T cell immunity. Science. 322:1097–1100. 
http://dx.doi.org/10.1126/science.1164206
Hogquist, K.A., S.C. Jameson, W.R. Heath, J.L. Howard, M.J. Bevan, and F.R. 
Carbone. 1994. T cell receptor antagonist peptides induce positive selec­
tion. Cell. 76:17–27. http://dx.doi.org/10.1016/0092­8674(94)90169­4
Huang, A.Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. 
Levitsky. 1994. Role of bone marrow­derived cells in presenting MHC 
class I­restricted tumor antigens. Science. 264:961–965. http://dx.doi 
.org/10.1126/science.7513904
Jablonska, J., S. Leschner, K. Westphal, S. Lienenklaus, and S. Weiss. 2010. 
Neutrophils responsive to endogenous IFN­beta regulate tumor angio­
genesis and growth in a mouse tumor model. J. Clin. Invest. 120:1151–
1164. http://dx.doi.org/10.1172/JCI37223
Kamphuis,  E.,  T.  Junt,  Z.  Waibler,  R.  Forster,  and  U.  Kalinke.  2006. 
Type I interferons directly regulate lymphocyte recirculation and cause 
transient  blood  lymphopenia.  Blood.  108:3253–3261.  http://dx.doi 
.org/10.1182/blood­2006­06­027599
Kaplan, D.H., V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, and 
R.D. Schreiber. 1998. Demonstration of an interferon gamma­dependent 
tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. 
Sci. USA. 95:7556–7561. http://dx.doi.org/10.1073/pnas.95.13.7556
Kärre, K., H.G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective re­
jection of H­2­deficient lymphoma variants suggests alternative immune 
defence strategy. Nature. 319:675–678. http://dx.doi.org/10.1038/ 
319675a0
Koebel, C.M., W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old, M.J. 
Smyth, and R.D. Schreiber. 2007. Adaptive immunity maintains occult 
cancer in an equilibrium state. Nature. 450:903–907. http://dx.doi.org/ 
10.1038/nature06309
Kolumam, G.A., S. Thomas, L.J. Thompson, J. Sprent, and K. Murali­
Krishna. 2005. Type I interferons act directly on CD8 T cells to allow 
clonal expansion and memory formation in response to viral infection.   
J. Exp. Med. 202:637–650. http://dx.doi.org/10.1084/jem.20050821
Koo, G.C., and J.R. Peppard. 1984. Establishment of monoclonal anti­
Nk­1.1 antibody. Hybridoma. 3:301–303. http://dx.doi.org/10.1089/ 
hyb.1984.3.301
Le Bon, A., G. Schiavoni, G. D’Agostino, I. Gresser, F. Belardelli, and 
D.F. Tough. 2001. Type i interferons potently enhance humoral im­
munity  and  can  promote  isotype  switching  by  stimulating  dendritic 
cells in vivo. Immunity. 14:461–470. http://dx.doi.org/10.1016/S1074­ 
7613(01)00126­1
Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. 
Borrow, and D.F. Tough. 2003. Cross­priming of CD8+ T cells stimu­
lated by virus­induced type I interferon. Nat. Immunol. 4:1009–1015. 
http://dx.doi.org/10.1038/ni978
Le Bon, A., V. Durand, E. Kamphuis, C. Thompson, S. Bulfone­Paus, C. 
Rossmann, U. Kalinke, and D.F. Tough. 2006a. Direct stimulation of 
T cells by type I IFN enhances the CD8+ T cell response during cross­
priming. J. Immunol. 176:4682–4689.
Le Bon, A., C. Thompson, E. Kamphuis, V. Durand, C. Rossmann, U. 
Kalinke, and D.F. Tough. 2006b. Cutting edge: enhancement of anti­
body responses through direct stimulation of B and T cells by type I IFN.   
J. Immunol. 176:2074–2078.
Longhi, M.P., C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, C. Kluger, 
A.M. Salazar, M. Colonna, and R.M. Steinman. 2009. Dendritic cells 
require a systemic type I interferon response to mature and induce CD4+ 
Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206:1589–1602. 
http://dx.doi.org/10.1084/jem.20090247
Lorenzi, S., F. Mattei, A. Sistigu, L. Bracci, F. Spadaro, M. Sanchez, M. 
Spada, F. Belardelli, L. Gabriele, and G. Schiavoni. 2011. Type I IFNs 
control antigen retention and survival of CD8(+) dendritic cells after 
uptake of tumor apoptotic cells leading to cross­priming. J. Immunol. 
186:5142–5150. http://dx.doi.org/10.4049/jimmunol.1004163
Luft, T., K.C. Pang, E. Thomas, P. Hertzog, D.N. Hart, J. Trapani, and 
J. Cebon. 1998. Type I IFNs enhance the terminal differentiation of 
dendritic cells. J. Immunol. 161:1947–1953.
Christensen,  J.L.,  D.E.  Wright,  A.J.  Wagers,  and  I.L.  Weissman.  2004. 
Circulation and chemotaxis of fetal hematopoietic stem cells. PLoS Biol. 
2:E75. http://dx.doi.org/10.1371/journal.pbio.0020075
Clausen, B.E., C. Burkhardt, W. Reith, R. Renkawitz, and I. Förster. 
1999.  Conditional  gene  targeting  in  macrophages  and  granulocytes 
using LysMcre mice. Transgenic Res. 8:265–277. http://dx.doi.org/10 
.1023/A:1008942828960
Cobbold, S.P., A. Jayasuriya, A. Nash, T.D. Prospero, and H. Waldmann. 1984.   
Therapy  with  monoclonal  antibodies  by  elimination  of  T­cell  subsets   
in vivo. Nature. 312:548–551. http://dx.doi.org/10.1038/312548a0
Coro, E.S., W.L. Chang, and N. Baumgarth. 2006. Type I IFN receptor   
signals directly stimulate local B cells early following influenza virus   
infection. J. Immunol. 176:4343–4351.
Curtsinger, J.M., J.O. Valenzuela, P. Agarwal, D. Lins, and M.F. Mescher. 
2005. Type I IFNs provide a third signal to CD8 T cells to stimulate 
clonal expansion and differentiation. J. Immunol. 174:4465–4469.
Dialynas, D.P., Z.S. Quan, K.A. Wall, A. Pierres, J. Quintáns, M.R. Loken, 
M.  Pierres,  and  F.W.  Fitch.  1983.  Characterization  of  the  murine   
T cell surface molecule, designated L3T4, identified by monoclonal   
antibody GK1.5: similarity of L3T4 to the human Leu­3/T4 molecule. 
J. Immunol. 131:2445–2451.
Dighe, A.S., E. Richards, L.J. Old, and R.D. Schreiber. 1994. Enhanced 
in vivo growth and resistance to rejection of tumor cells expressing 
dominant negative IFN gamma receptors. Immunity. 1:447–456. http://
dx.doi.org/10.1016/1074­7613(94)90087­6
Dudziak,  D.,  A.O.  Kamphorst,  G.F.  Heidkamp,  V.R.  Buchholz,  C. 
Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H.W. Lee, C.G. Park,   
et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. 
Science. 315:107–111. http://dx.doi.org/10.1126/science.1136080
Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber. 2002. 
Cancer  immunoediting:  from  immunosurveillance  to  tumor  escape. 
Nat. Immunol. 3:991–998. http://dx.doi.org/10.1038/ni1102­991
Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004. The three Es of can­
cer immunoediting. Annu. Rev. Immunol. 22:329–360. http://dx.doi 
.org/10.1146/annurev.immunol.22.012703.104803
Dunn, G.P., A.T. Bruce, K.C. Sheehan, V. Shankaran, R. Uppaluri, J.D. 
Bui, M.S. Diamond, C.M. Koebel, C. Arthur, J.M. White, and R.D. 
Schreiber. 2005. A critical function for type I interferons in cancer   
immunoediting. Nat. Immunol. 6:722–729. http://dx.doi.org/10.1038/ 
ni1213
Dunn, G.P., C.M. Koebel, and R.D. Schreiber. 2006. Interferons, immunity 
and cancer immunoediting. Nat. Rev. Immunol. 6:836–848. http://dx.doi 
.org/10.1038/nri1961
Edelson, B.T., W. Kc, R. Juang, M. Kohyama, L.A. Benoit, P.A. Klekotka, 
C. Moon, J.C. Albring, W. Ise, D.G. Michael, et al. 2010. Peripheral 
CD103+ dendritic cells form a unified subset developmentally related to 
CD8+ conventional dendritic cells. J. Exp. Med. 207:823–836. http://
dx.doi.org/10.1084/jem.20091627
Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endog­
enous activators of dendritic cells. Nat. Med. 5:1249–1255. http://dx.doi 
.org/10.1038/15200
Ginhoux, F., K. Liu, J. Helft, M. Bogunovic, M. Greter, D. Hashimoto, J. 
Price, N. Yin, J. Bromberg, S.A. Lira, et al. 2009. The origin and devel­
opment of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206:3115–
3130. http://dx.doi.org/10.1084/jem.20091756
Gogas, H., J. Ioannovich, U. Dafni, C. Stavropoulou­Giokas, K. Frangia, 
D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, 
et al. 2006. Prognostic significance of autoimmunity during treatment 
of melanoma with interferon. N. Engl. J. Med. 354:709–718. http://
dx.doi.org/10.1056/NEJMoa053007
Havenar­Daughton,  C.,  G.A.  Kolumam,  and  K.  Murali­Krishna.  2006. 
Cutting Edge: The direct action of type I IFN on CD4 T cells is critical 
for sustaining clonal expansion in response to a viral but not a bacterial 
infection. J. Immunol. 176:3315–3319.
Heath, W.R., G.T. Belz, G.M. Behrens, C.M. Smith, S.P. Forehan, I.A. 
Parish, G.M. Davey, N.S. Wilson, F.R. Carbone, and J.A. Villadangos. 
2004. Cross­presentation, dendritic cell subsets, and the generation of 
immunity to cellular antigens. Immunol. Rev. 199:9–26. http://dx.doi 
.org/10.1111/j.0105­2896.2004.00142.xJEM Vol. 208, No. 10 
Article
2003
mary tumour development and shape tumour immunogenicity. Nature. 
410:1107–1111. http://dx.doi.org/10.1038/35074122
Sheehan, K.C., K.S. Lai, G.P. Dunn, A.T. Bruce, M.S. Diamond, J.D. 
Heutel,  C.  Dungo­Arthur,  J.A.  Carrero,  J.M.  White,  P.J.  Hertzog, 
and R.D. Schreiber. 2006. Blocking monoclonal antibodies specific for 
mouse IFN­alpha/beta receptor subunit 1 (IFNAR­1) from mice im­
munized by in vivo hydrodynamic transfection. J. Interferon Cytokine 
Res. 26:804–819. http://dx.doi.org/10.1089/jir.2006.26.804
Smyth,  M.J.,  G.P.  Dunn,  and  R.D.  Schreiber.  2006.  Cancer  immuno­
surveillance and immunoediting: the roles of immunity in suppressing   
tumor development and shaping tumor immunogenicity. Adv. Immunol. 
90:1–50. http://dx.doi.org/10.1016/S0065­2776(06)90001­7
Spiotto, M.T., D.A. Rowley, and H. Schreiber. 2004. Bystander elimina­
tion of antigen loss variants in established tumors. Nat. Med. 10:294–
298. http://dx.doi.org/10.1038/nm999
Steinman, R.M., and J. Banchereau. 2007. Taking dendritic cells into medi­
cine. Nature. 449:419–426. http://dx.doi.org/10.1038/nature06175
Steinman, R.M., D. Hawiger, and M.C. Nussenzweig. 2003. Tolerogenic den­
dritic cells. Annu. Rev. Immunol. 21:685–711. http://dx.doi.org/10.1146/ 
annurev.immunol.21.120601.141040
Stetson, D.B., and R. Medzhitov. 2006. Type I interferons in host defense. 
Immunity.  25:373–381.  http://dx.doi.org/10.1016/j.immuni.2006 
.08.007
Stranges, P.B., J. Watson, C.J. Cooper, C.M. Choisy­Rossi, A.C. Stonebraker, 
R.A. Beighton, H. Hartig, J.P. Sundberg, S. Servick, G. Kaufmann,   
et al. 2007. Elimination of antigen­presenting cells and autoreactive 
T cells by Fas contributes to prevention of autoimmunity. Immunity. 
26:629–641. http://dx.doi.org/10.1016/j.immuni.2007.03.016
Street, S.E., E. Cretney, and M.J. Smyth. 2001. Perforin and interferon­
gamma  activities  independently  control  tumor  initiation,  growth, 
and  metastasis.  Blood.  97:192–197.  http://dx.doi.org/10.1182/blood 
.V97.1.192
Street,  S.E.,  J.A.  Trapani,  D.  MacGregor,  and  M.J.  Smyth.  2002. 
Suppression of lymphoma and epithelial malignancies effected by inter­
feron gamma. J. Exp. Med. 196:129–134. http://dx.doi.org/10.1084/ 
jem.20020063
Swann,  J.B.,  Y.  Hayakawa,  N.  Zerafa,  K.C.  Sheehan,  B.  Scott,  R.D. 
Schreiber, P. Hertzog, and M.J. Smyth. 2007. Type I IFN contributes 
to NK cell homeostasis, activation, and antitumor function. J. Immunol. 
178:7540–7549.
Thompson, L.J., G.A. Kolumam, S. Thomas, and K. Murali­Krishna. 2006. 
Innate inflammatory signals induced by various pathogens differentially 
dictate the IFN­I dependence of CD8 T cells for clonal expansion and 
memory formation. J. Immunol. 177:1746–1754.
Vesely, M.D., M.H. Kershaw, R.D. Schreiber, and M.J. Smyth. 2011. Natural 
innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29:235–
271. http://dx.doi.org/10.1146/annurev­immunol­031210­101324
Wolkers,  M.C.,  G.  Stoetter,  F.A.  Vyth­Dreese,  and  T.N.  Schumacher. 
2001.  Redundancy  of  direct  priming  and  cross­priming  in  tumor­ 
specific CD8+ T cell responses. J. Immunol. 167:3577–3584.
Zietara, N., M. Łyszkiewicz, N. Gekara, J. Puchałka, V.A. Dos Santos, 
C.R. Hunt, T.K. Pandita, S. Lienenklaus, and S. Weiss. 2009. Absence 
of  IFN­beta  impairs  antigen  presentation  capacity  of  splenic  den­
dritic cells via down­regulation of heat shock protein 70. J. Immunol. 
183:1099–1109.
Lybarger, L., X. Wang, M.R. Harris, H.W. Virgin IV, and T.H. Hansen. 2003. 
Virus subversion of the MHC class I peptide­loading complex. Immunity. 
18:121–130. http://dx.doi.org/10.1016/S1074­7613(02)00509­5
Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep 
activated T cells alive. J. Exp. Med. 189:521–530. http://dx.doi.org/ 
10.1084/jem.189.3.521
Melief,  C.J.  2008.  Cancer  immunotherapy  by  dendritic  cells.  Immunity. 
29:372–383. http://dx.doi.org/10.1016/j.immuni.2008.08.004
Mombaerts, P., J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa, and 
V.E.  Papaioannou.  1992.  RAG­1­deficient  mice  have  no  mature   
B and T lymphocytes. Cell. 68:869–877. http://dx.doi.org/10.1016/ 
0092­8674(92)90030­G
Montoya, M., G. Schiavoni, F. Mattei, I. Gresser, F. Belardelli, P. Borrow, 
and D.F. Tough. 2002. Type I interferons produced by dendritic cells 
promote their phenotypic and functional activation. Blood. 99:3263–
3271. http://dx.doi.org/10.1182/blood.V99.9.3263
Mumberg,  D.,  P.A.  Monach,  S. Wanderling,  M.  Philip, A.Y. Toledano,  R.D. 
Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class   
II­negative cancer cells in vivo by indirect effects of IFN­gamma. Proc. Natl. 
Acad. Sci. USA. 96:8633–8638. http://dx.doi.org/10.1073/pnas.96.15.8633
Nguyen, K.B., T.P. Salazar­Mather, M.Y. Dalod, J.B. Van Deusen, X.Q. Wei, 
F.Y. Liew, M.A. Caligiuri, J.E. Durbin, and C.A. Biron. 2002. Coordinated 
and distinct roles for IFN­alpha beta, IL­12, and IL­15 regulation of NK 
cell responses to viral infection. J. Immunol. 169:4279–4287.
Ochsenbein, A.F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, 
S. Hemmi, H. Hengartner, and R.M. Zinkernagel. 2001. Roles of tumour 
localization, second signals and cross priming in cytotoxic T­cell induction. 
Nature. 411:1058–1064. http://dx.doi.org/10.1038/35082583
Pilz, A., W. Kratky, S. Stockinger, O. Simma, U. Kalinke, K. Lingnau, A. 
von Gabain, D. Stoiber, V. Sexl, T. Kolbe, et al. 2009. Dendritic cells 
require STAT­1 phosphorylated at its transactivating domain for the 
induction of peptide­specific CTL. J. Immunol. 183:2286–2293. http://
dx.doi.org/10.4049/jimmunol.0901383
Prinz, M., H. Schmidt, A. Mildner, K.P. Knobeloch, U.K. Hanisch, J. 
Raasch, D. Merkler, C. Detje, I. Gutcher, J. Mages, et al. 2008. Distinct 
and nonredundant in vivo functions of IFNAR on myeloid cells limit 
autoimmunity in the central nervous system. Immunity. 28:675–686. 
http://dx.doi.org/10.1016/j.immuni.2008.03.011
Qin, Z., and T. Blankenstein. 2000. CD4+ T cell—mediated tumor rejec­
tion involves inhibition of angiogenesis that is dependent on IFN gamma 
receptor expression by nonhematopoietic cells. Immunity. 12:677–686. 
http://dx.doi.org/10.1016/S1074­7613(00)80218­6
Qin,  Z.,  J.  Schwartzkopff,  F.  Pradera,  T.  Kammertoens,  B.  Seliger,  H. 
Pircher, and T. Blankenstein. 2003. A critical requirement of interferon 
gamma­mediated angiostasis for tumor rejection by CD8+ T cells. 
Cancer Res. 63:4095–4100.
Schreiber, R.D., L.J. Hicks, A. Celada, N.A. Buchmeier, and P.W. Gray. 
1985. Monoclonal antibodies to murine gamma­interferon which dif­
ferentially  modulate  macrophage  activation  and  antiviral  activity.   
J. Immunol. 134:1609–1618.
Schreiber, R.D., L.J. Old, and M.J. Smyth. 2011. Cancer immunoedit­
ing: integrating immunity’s roles in cancer suppression and promotion. 
Science. 331:1565–1570. http://dx.doi.org/10.1126/science.1203486
Shankaran, V., H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, 
and R.D. Schreiber. 2001. IFNgamma and lymphocytes prevent pri­